Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

KT-253

Small molecule · Degrader of MDM2 · developed by Kymera Therapeutics

Phase 1 Most advanced trial (none active)
KYMR Developer
1 Registered trials

What is KT-253?

KT-253 is a small molecule protein degrader that binds MDM2 and the E3 ubiquitin ligase, targeting MDM2 for proteasomal degradation. This restores p53 transcriptional activity and p53-mediated tumor cell apoptosis. It is being studied in myeloid malignancies, acute lymphocytic leukemia, lymphomas and advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
MDM2
Mechanism
Degrader of MDM2
Pathways
p53 pathway, proteasome-mediated degradation, p53-mediated apoptosis
Therapy area
Oncology
Developer
Kymera Therapeutics, Inc. (KYMR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05775406 Phase 1 Myeloid Malignancies Completed KYMR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Lymphocytic LeukemiaAdvanced Solid TumorsLymphomasMyeloid Malignancies

Other drugs acting on MDM2

More from Kymera Therapeutics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KYMR page.

Follow KYMR, the company behind KT-253

See KYMR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KYMR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.